Formosa Pharmaceuticals Announces Successful Top-Line Results from CPN-303, a Phase 3 Trial in Chinese Subjects for the Treatment of Inflammation and Pain after Cataract Surgery
TAIPEI, Nov. 4, 2024 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. (6838.TW) reports completion and successful top-line results from CPN-303, a Phase 3 clinical study of APP13007 (GPN00833), conducted in Chinese cataract